Targets › GLP2R
4 programs from 4 companies in 5 trials: 4 Phase 3, 1 Phase 2; Gastroenterology, Immunology; next expected readout Feb 2027.
This is a receptor for glucagon-like peptide 2. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. (UniProt, O95838)
Open in Phaseline: the race on GLP2R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Takeda | Teduglutide Glucagon-like peptide 2 receptor agonist | GLP2R | Phase 3 | Short Bowel Syndrome | Feb 2027 |
| Chongqing Peg-Bio Biopharm | PJ009 Glucagon-like peptide-2 (GLP-2) receptor agonist | GLP2R | Phase 3 | Short Bowel Syndrome | Mar 2027 |
| VectivBio | Apraglutide GLP-2 receptor agonist | GLP2R | Phase 3 | Short Bowel Syndrome; Short Bowel Syndrome (SBS) | Oct 2027 |
| University Hospital, Gentofte, Copenhagen | Dapiglutide Dual GLP-1R/GLP-2R agonist | GLP1R, GLP2R | Phase 2 | Obesity | – |
Short Bowel Syndrome (3) Short Bowel Syndrome (SBS) (1) Obesity (1)
protein or peptide (4)
VectivBio (1) Chongqing Peg-Bio Biopharm (1) University Hospital, Gentofte, Copenhagen (1) Takeda (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.